Treatment of Jianpi Shugan recipe in the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D)

Submission date	Recruitment status	[X] Prospectively registered
19/03/2015	No longer recruiting	[_] Protocol
Registration date	Overall study status	[] Statistical analysis plan
08/04/2015	Completed	[_] Results
Last Edited Condition category	Individual participant data	
08/04/2015	Digestive System	[] Record updated in last year

Plain English Summary

Background and study aims.

Diarrhoea-predominant irritable bowel syndrome (IBS-D) affects around 3% of the population and is characterised by abdominal pain and frequent loose bowel movements. There are few treatments for these symptoms that work and this study aims to see whether Jianpi Shugan recipe might help those with IBS-D. Previous studies have suggested a benefit but this needs to be confirmed.

Who can participate?

Patients diagnosed by their doctors as having diarrhoea-predominant irritable bowel syndrome .

What does the study involve?

Patients will be randomly allocated either to take Jianpi Shugan recipe herbal granules with a placebo (dummy) tablet, or to take Pinaverium with placebo granules for 4 weeks. At the beginning of the study, an examination of the lower bowel will be made and a small specimen taken from the lining (biopsy). This procedure is routinely performed to identify the different causes of diarrhoea.

What are the possible benefits and risks of participating? We are hoping that towards the end of the 4-week period diarrhoea and abdominal pain will improve. The drugs has been used for many years and the side effects are well recognised. Only a very few will not tolerate the drug because of abdominal discomfort, constipation, diarrhoea, nausea, rash etc.

Where is the study run from?

Beijing Hospital of Traditional Chinese Medicine affiliated to Capital Medical University Beijing Chaoyang Hospital affiliated to Capital Medical University The First Affiliated Hospital of Henan University of TCM First Teaching Hospital of Tianjin University of TCM Second Affiliated Hospital of Tianjin University of TCM When is the study starting and how long is it expected to run for? From April 2015 and to March 2016.

Who is funding the study? Beijing municipal administration of hospitals (China).

Who is the main contact? Dr Shengsheng Zhang zhss2000@163.com

Contact information

Type(s) Scientific

Contact name Dr Luqing Zhao

ORCID ID http://orcid.org/0000-0003-1986-3511

Contact details

Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University No. 23 Meishuguan Back Street Dongcheng District Beijing China 100010

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers N/A

Study information

Scientific Title

Efficacy of Jianpi Shugan recipe in the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D): a multicentre parallel-group randomised controlled trial

Study hypothesis

The purpose of the trial is to define the clinical benefit of Jianpi Shugan recipe in diarrhoeapredominant irritable bowel syndrome (IBS-D) . The primary endpoint is to assess the effect of Jianpi Shugan recipe on IBS Symptom Severity Score (IBS-SSS).

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethics committee of Beijing Hospital of Traditional Chinese Medicine affiliated to Capital Medical University, 15/02/2015, NO.2015BL-008-02

Study design

Multicentre parallel-group double-blind randomised controlled trial

Primary study design Interventional

Secondary study design

Randomised parallel trial

Study setting(s) Hospital

Study type(s) Treatment

Participant information sheet

Condition

Diarrhoea-predominant irritable bowel syndrome (IBS-D)

Interventions

Patients will be randomized to receive either Jianpi Shugan recipe herbal granules + matching Pinaverium placebo or Pinaverium + matching Jianpi Shugan recipe herbal placebo granules for 4 weeks. Herbal granules were dissolved in 300 ml of boiled water, 150 ml twice daily, Pinaverium 50 mg three times a day.

Intervention Type Drug

Phase Not Applicable

Drug/device/biological/vaccine name(s)

Pinaverium

Primary outcome measure

IBS Symptom Severity Score (IBS-SSS) measured at baseline, 2 weeks and 4 weeks

Secondary outcome measures

1. Traditional Chinese Medicine syndromes of IBS score measured at baseline, 2 weeks and 4 weeks

2. Defection state questionnaire (DSQ) for IBS noted by patients daily

3. Irritable bowel syndrome-quality of life questionnaire (IBS-QOL) at baseline and 4 weeks

4. Serum concentration of serotonin at baseline and 4 weeks

Overall study start date

01/04/2015

Overall study end date 31/03/2016

Eligibility

Participant inclusion criteria

1. Patients with IBS-D meeting the Rome III criteria

2. Patients meeting the Traditional Chinese Medicine syndrome of liver-depression and spleendeficiency criteria

3. Patients able to give informed consent

4. Female patients of childbearing potential are willing to use at least one highly effective contraceptive method

5. Aged 18-65 years, either sex

Participant type(s) Patient

Age group Adult

Lower age limit

18 Years

Upper age limit 65 Years

Sex

Both

Target number of participants 260

Participant exclusion criteria

1. Women who are pregnant or breastfeeding

2. Prior abdominal surgery which may cause bowel symptoms similar to IBS

3. Patients with the following diarrhea conditions: infection, systemic diseases, poisoning or cancer

4. Patients with serious concomitant diseases e.g. cardiovascular, renal, hepatic, respiratory, neurological, endocrine, hematopoietic etc

5. Patients with a history of alcoholic or drug abuse

6. Patients who have allergic constitution or known to be allergic to the drug used in this trial

7. Patients who are involved in other trials

8. Patients with poor compliance or other reasons that the researcher considered not to be appropriate to participate in this trial

Recruitment start date 01/06/2015

Recruitment end date 01/03/2016

Locations

Countries of recruitment China

Study participating centre Beijing Hospital of Traditional Chinese Medicine affiliated to Capital Medical University Beijing China 100010

Study participating centre Beijing Chaoyang Hospital affiliated to Capital Medical University Beijing China

Study participating centre The First Affiliated Hospital of Henan University of TCM Zhengzhou China

Study participating centre First Teaching Hospital of Tianjin University of TCM Tianjin China

Study participating centre Second Affiliated Hospital of Tianjin University of TCM Tianjin China

Sponsor information

Organisation Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University

Sponsor details

No. 23 Meishuguan Back Street Dongcheng District Beijing China 100010

Sponsor type Hospital/treatment centre

ROR https://ror.org/057vq6e26

Funder(s)

Funder type Hospital/treatment centre

Funder Name Beijing municipal administration of hospitals

Results and Publications

Publication and dissemination plan To be confirmed at a later date

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary Available on request